Atezolizumab plus platinum-based chemotherapy and etoposide as first-line treatment for metastatic small cell lung cancer: a retrospective multicenter observational study

Key Points

• High response rates and acceptable survival were observed with atezolizumab plus platinum-etoposide in extensive-stage small cell lung cancer.
• Patients with hepatic metastases or poor ECOG performance status faced worse survival outcomes, indicating the need for careful prognostic assessment.
• Data were drawn from a retrospective multicenter observational approach, providing real-world evidence but lacking a randomized control group.
• These findings support using atezolizumab in certain patients but highlight the necessity of further controlled trials for validation.

Abstract